Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2020 Nov 23;4(1):1–13. doi: 10.1007/s42250-020-00203-x

Natural and Synthetic Drugs as Potential Treatment for Coronavirus Disease 2019 (COVID-2019)

Saba Farooq 1,, Zainab Ngaini 1,
PMCID: PMC7682129

Abstract

Coronavirus disease 2019 (COVID-19) has become a global pandemic in a short period, where a tragically large number of human lives being lost. It is an infectious pandemic that recently infected more than two hundred countries in the world. Many potential treatments have been introduced, which are considered potent antiviral drugs and commonly reported as herbal or traditional and medicinal treatments. A variety of bioactive metabolites extracts from natural herbal have been reported for coronaviruses with some effective results. Food and Drug Administration (FDA) has approved numerous drugs to be introduced against COVID-19, which commercially available as antiviral drugs and vaccines. In this study, a comprehensive review is discussed on the potential antiviral remedies based on natural and synthetic drugs. This review highlighted the potential remedies of COVID-19 which successfully applied to patients with high cytopathic inhibition potency for cell-to-cell spread and replication of coronavirus.

Keywords: Antivirus, Chloroquine, Dosage, Pandemic, Plasma, Ivermectin

Introduction

The emergence of recent coronavirus disease 2019 (COVID-19) has become an alarming issue and shaken the whole world. The new pathogenic strain [1] produced by coronavirus has infected millions of people worldwide that led to massive death since December 2019 [2]. COVID-19 was first identified in Wuhan, China from an unknown source of coronavirus, which gradually spread to the whole world [37] and tragically affected human life. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19 in humans and animals [814]. COVID-19 has a similarity with the earlier reported disease called severe acute respiratory syndrome (SARS) caused by severe acute respiratory syndrome coronavirus (SARS-CoV), regarding their symptoms i.e. cough, fatigue, fever, and lower respiratory sign [1517]. The current pandemic has compelled the researchers to explore new effective drugs against COVID-19.

SARS-CoV-2 is structurally similar to other coronavirus and is only differentiated by the prominent spike of proteins [18]. Coronaviruses belong to positive single-strand long RNA viruses [19, 20] with numerous structural proteins i.e. envelope (E), spike (S) [21], membrane (M), nucleocapsid (N) proteins contributing or assisting virus for replication [22] and entry in the host [23]. Both SARS-CoV and SARS-CoV-2 have common angiotensin-converting enzyme 2 (ACE2) used as a receptor that is responsible for the respiratory syndrome. Startlingly, the spike-glycoprotein plays an important role for a strong guest host binding with the targets receptor [24]. The Mpro enzyme contributed to the viral replication of coronavirus [25]. The viral proteases (PL-pro and 3-CL pro) are contributed to the cleavage of replicate polyproteins, significant for viral replication [26]. SARS-CoV-2 can also enter into the host via endosomes at low pH, which can be controlled by increasing pH [27]. A comprehensive illustration of the SARS-CoV-2 structure, replication cycle and immune system response is depicted in (Fig. 1) [28, 29].

Fig. 1.

Fig. 1

Diagrammatic depiction of SARS-CoV-2 structure (a); replications process (b) and immune response (c)

The phylogenetic tree of coronaviruses consists of four types i.e. α-coronavirus, β-coronavirus, γ-coronavirus, δ-coronavirus [30]. Phylogeny and genomic analysis declared SARS-CoV-2 is belonged to β-coronavirus [31, 32]. Previously reported coronaviruses such as corona-SARS [3336], infectious bronchitis virus (IBV) [37, 38], mouse hepatitis coronavirus (MHV) [3942], feline infectious peritonitis (FIP) [43], human immunodeficiency virus (HIV) [44] and hepatitis C virus (HCV) [45], canine coronavirus [46], which originated from different sources such as bats [4749], chicken, pig, mouse and rat [50]. Coronavirus diseases are triggered by cytopathogenicity [51] and virus multiplication in the human body such as the respiratory tract [52, 53], intestines, kidneys and brain [54, 55], and extensively spread from human to another human. Nevertheless, coronavirus is spread via a secondary mode of transmission very quickly in numerous countries of the world. The best strategies have been imposed to reduce social contact [5658] as well as enforcing Chinese rules and restrictions [59]. Unfortunately, the number of cases of highly contagious [60] COVID-19 is still increasing due to the fast viral replication [61], poor quarantine [62, 63] and human to human transmission [64, 65] through touching, coughing and sneezing [66, 67].

Coronavirus is mainly attacked on the respiratory system and also damages myocardial tissues [68, 69] and gastrointestinal organs [70]. Many common factors could seriously put patients at high risk such as (1) nature of drug/medicine, (2) dosage/potency of the drug, (3) condition of the patient (i.e. aging, obesity, sex [71], diabetes, kidney illness [72, 73], liver disease [74], anxiety/ stress [75], pregnancy [76]). The existing connection between diabetes and obesity contributes to significant hazardous factors impacting the therapeutic severity of SARS-CoV-2 infections [77]. An ability to boost the body's immune system may significantly affect the medicinal remedies for COVID-19 treatment as a person to person immunity strength varies [78]. It equally affected young and old people. However, the affected ratio of females is lower compared to males due to a versatile hormonal system and immunity set up [79].

Based on literature precedent, exhaustive efforts have been carried out to produce effective antiviral drugs to control coronavirus infection and replication [80, 81] in entry host and to enhance the host immune response [82, 83] might take several years before it’s become commercially available. Many reviews [8494] reported on the types, transmission or origin of coronavirus. In this review, natural and synthetic drugs-based treatments illustrated for COVID-19 and the outcomes of their drug’s potential is thoroughly discussed.

Types of Treatment for COVID-2019

Numerous treatment methods have been reported to cure COVID-19. Among various treatments, natural and synthetic remedies are the most commonly reported. Other strategies involved in the inactivation of pathogens especially on coronavirus infections have also been widely reported such as UV A [95], UV C light [96], heat sensitivity [97] octanoic acid treatment [98], to name a few. The photodynamic and thermodynamic treatment strategies are involved penetration of UV light/heat into the fluid of platelet and inactivation of pathogenic microorganisms and leucocytes to damage the nucleic acids from continue spreading the viral.

Natural Treatment

The natural remedy is a naturally occurring secondary metabolite extracted from living organisms such as plants, animals, fungi and bacteria having potential antiviral agents [99]. The natural remedies are remarked as virtuous sources for the development and production of antiviral agents [100, 101]. Several metabolites derived from plants and animals have been recounted with antitumor, antifungal, antiinflammatory and antiviral properties [102, 103]. In Asian countries, herbal plant treatment has been conventionally used for many pharmaceutical purposes [104].

Plants-Based Treatment

Many studies reported on plants based natural products as alleged remedies for viral infection [105]. The bioactive metabolites from various parts of plant extract i.e. stems, seeds, roots and leaves have been widely reported with antiviral properties. Stephania tetrandra or Menispermaceae are examples of plants with excellent sources of bis-benzylisoquinoline alkaloids namely fangchinoline (1), tetrandrine (2) and cepharanthine (3). Compound (13) has been reported to inhibit protein expression, repress infectivity, and inhibit the replication of coronavirus in human and virus-induced host reappearance. Natural remedies from active metabolites (13) in the plant are beneficial and convenient for potential treatment and anticipation of COVID-19 (Fig. 2) [106].

Fig. 2.

Fig. 2

Stephania plants extracted drugs for COVID-19 in human

In Asia, conventional remedies based upon natural resources namely garlic, cardamom, pennyroyal, liquorice, pepper, turmeric, tragacanth and hedge nettle (Fig. 3) have been alleged for an effective cure against coronavirus diseases. Among these conventional remedies, curcumin, a secondary metabolite derived from turmeric, is more conspicuous and widely reported for potential COVID-19 treatment due to stronger interaction with protease enzyme as compared to other natural compounds (i.e. pepper, pennyroyal, tragacanth) [107].

Fig. 3.

Fig. 3

Asian conventional natural remedies

Chinese natural remedies have been renowned as imperative traditional remedies due to high efficiency, negligible and less side effects [108]. Chinese traditional herbs often offer rapid remedies for virus outbreak. Gancao (1), fangfeng (2), baizhu (3), jinyinhua (4) and huangqi (5) are examples of Chinese natural herbs that contain good antiviral potency with significant consequences (Fig. 4) [109, 110]. A commercial natural drug called Lianhua Qingwen is another Chinese herb derived from a combination of yinhuapinggan granule and San Wu huangqin decoction has been recently reported to cure COVID-19 in Beijing, China [111].

Fig. 4.

Fig. 4

Chinese natural herbs as antiviral (a) and frequency of natural herbs for COVID-19 (b)

Human/Animal-Based Treatment

Human or animal-derived remedies are significantly based upon the production of hormones, antibodies, secretion to the treatment of diseases. Plasma treatment is an example of specifically used remedies in the critical stage of COVID-19 treatment.

Plasma Treatment

Utilizing plasma from human blood who has recuperated from illness has been an alternative method to cure COVID-19. Plasma contains a natural antibody [112] which is helpful for the critical stage treatment known as plasma treatment of passive antibody therapy (Fig. 5) [113]. Human ‘sera’ of convalescent patients (coronavirus disease recovered patients) cross neutralized SARS-CoV-2 S-driven entry [114, 115]. Convalescent plasma has successfully contributed to the COVID-19 recovery after the transfusion of plasma to bring the patient to the normal body temperature [116]. Plasma exchange therapy is an old treatment but found it helpful to fight for fatal COVID-19 [117]. Serological tests were recorded for confirmation of the efficiency of antibodies for coronavirus disease treatment via neutralization before the usage of plasma [118, 119].

Fig. 5.

Fig. 5

Passive antibody therapy or plasma treatment for COVID-19

© American Society for Clinical Investigation

The spike protein is responsible for the formation of severe respiratory infection through the coronavirus by fusion or correlating with cellular receptors to target cells [120]. The ACE2 (angiotensin-converting enzyme 2) is a carboxypeptidase, which effectively terminates angiotensin II to angiotensin, has been recognized as a potent receptor for coronavirus. The recombinant protein achieved by the fusion of human extracellular domain ACE2 with the Fc section of human immunoglobulin IgG1 designated as ACE2-Ig contributed to the neutralization of spike protein [112]. The spike has a strong binding affinity with the receptor-binding domain (RBD) of coronaviruses and employs anticipated therapeutically properties [121]. In critical situations, plasma therapy is highly potential, more effective, easy to handle and safe for quick recovery of patients [122, 123].

Microorganisms-Based Treatment

Microorganisms such as algae, fungi and bacteria have also contained bioactive compounds and used to treat coronavirus [124]. Metabolites from fungal contained reactive moieties for protease inhibitors against SARS-CoV-2. Taxol or paclitaxel are examples of active metabolites extracted from fungal species i.e. Pestlotia, Pithomyces and have been reported for coronavirus treatments due to anti-HIV activity [125]. Patel and his coworkers have explored the fungal metabolites i.e. quercitrin (G. triplex), bergenin (D. indusiata) and dihydroartemisinin (C. stercoreus) through computational studies, which shows potential remedies to inhibit the main protease of SARS-CoV-2 [126].

Marine organisms are a well-known source for drug discovery in the therapeutic field [127]. Brown algae species such as Sargassum spinuligerum and Ecklonia cava has potential remedies against major protease protein of SARS-CoV-2 due to the presence of bioactive compounds 1,3,5-trihydroxybenzene and 8,8′-Bieckol, Dieckol, 6,6′-Bieckol [128, 129]. Moreover, microorganisms derived β-glucans can immune the body against coronavirus infections [130].

Synthetic Remedies

Western-style methods to cure any disease is recognized as allopathic treatment [131]. In cases of pneumonia and positive coronavirus test, antiviral drugs are recommended to the patients, but in emergency cases, supplementary oxygen is highly suggested [132134]. Due to quick spreading of COVID-19 crisis, previously reported antiviral, antimalarial or antiparasitic drugs (i.e. riboflavin [135], lopinavir [136], oseltamivir [137], lopinavir/ritonavir [138], minocycline [139], tocilizumab [140], ribavirin [141, 142], niclosamide [143], corticosteroids [144], and ciclesonide [145]) have been utilized for treatment. The clinical and laboratory trials are challenging to modern medicines [146148] that is still under investigation. The promising outcomes of few drugs are illustrated below:

Ivermectin

Ivermectin is a recognized Food and Drug Administration (FDA) approved antiparasitic drug [149] with potent antiviral activities [150]. Ivermectin, which previously reported to possess in vitro antiviral activity against a broad spectrum of coronaviruses [151, 152] has been recently reported as a potent inhibitor of SARS-CoV-2 infections with excellent ability to suppress pathogenic virus against in vero-hSLAM cells model. Caly et al. have recently reported on the effect of ivermectin on infected cells compared to the vehicle DMSO. Effective suppression of all viral materials after 48 h was demonstrated by the reduction in cell-associated viral RNA with an increase to an ~ 5000-fold in ivermectin-treated compared to control samples. The samples were prepared by using viral load through real-time PCR, then IC50 values were achieved using GraphPad prism after 48 h on cell-associated virus and supernatant against COVID-19 E-gene and RdRp gene by treating with different concentration of ivermectin. IC50 depicted ivermectin is potentially efficient against the inhibition of viral infection (Fig. 6) [153].

Fig. 6.

Fig. 6

FDA approved drug ivermectin

Remdesivir

Remdesivir (RDV) is another potential antiviral drug [154, 155] used to de-accelerate the RNA viral infections of SARS-CoV-2 (Fig. 7) [156]. It was reported by Holshue et al. on the successful recovery of COVID-19 patients by using remdesivir. Nevertheless, treating severe coronavirus patients with remdesivir [157] has not shown good responses. A comparative analysis of various drugs i.e. remdesivir, ribavirin [158], nitazoxanide, pencilovir, favipiravir, chloroquine and nafamostat has been comprehensively studied against COVID-19. The Vero E6 cells were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.05 and different concentrations of antiviral drugs for 48 h. The half-maximal effective concentration (EC50) values and cytotoxicity percentage were evaluated by qRT-PCR and CCK-8 assays, respectively, which depicted all drugs have good inhibition activities. Interestingly, the low-micromolar concentration or less dosage of remdesivir is more effective to cure fatal corona disease [159]. There are instances that excess dosage could damage human organs especially on lung tissue [160].

Fig. 7.

Fig. 7

Chemical structure of remdesivir

Chloroquine

Chloroquine is another well-known autoimmune and anti-malarial drug [161]. Chloroquine (Fig. 8) is a recognized drug to stop viral infection by enhancing the endosomal pH essential for the virus [162], besides intrusive the glycosylation of coronavirus cellular receptors [163]. The addition of chloroquine in the infected sample exhibited antiviral activity against COVID-19. Chloroquine has an immune-controlling activity, which interactively boosts up the in vivo antiviral effect. The drug is extensively reactive and distributed quickly to the whole body [159]. Essentially, the significance of chloroquine therapy is based upon age, stage of the disease and medicinal performance [164].

Fig. 8.

Fig. 8

Chemical structure of chloroquine

Hydroxychloroquine

Hydroxychloroquine (HCQ) (Fig. 9) [165] is a derivative of chloroquine and recently gazette as an authorized medicine for the treatment of corona disease [166]. A comparison of the properties of chloroquine and HCQ is depicted in Table 1 [163, 167, 168]. The severity of both HCQ and chloroquine can be reduced via assimilation with zinc supplement as zinc substance has been reported with a capability to reduce SARS-CoV-2 infection [169].

Fig. 9.

Fig. 9

Structure of hydroxychloroquine

Table 1.

Chloroquine and hydroxychloroquine comparison for COVID-19

Properties Chloroquine Hydroxychloroquine
Family Aminoquinolines Aminoquinolines
Availability Not common/limited Common
Toxic More Less
Nature Hazardous Safe
Solubility Less More
Oral toxicity More Less
Functioning inhibit viral infection inhibit viral infection

A recent study has been reported on the effective dosage of HCQ that can inhibit viral infection detected via WebPlotDigitizer (v4.2) software based on EC50. The observed EC50 was 4.7 µM, which is comparable to the in vitro EC50’s. The tremendous decrease in viral effect has been reported with HCQ doses > 400 mg twice in 1 day for ≥ 5 days against SARS-CoV-2 compared to the lower routine dose (≤ 400 mg daily). However, the HCQ > 600 mg dosage twice in 1 day was also effective. In contrast, the lower HCQ dose treatments may be insignificant to respond against the virus [170, 171].

Incorporation of HCQ with azithromycin has produced synergistic repletion in viral infection as the azithromycin drugs able to increase the efficacy of the drugs [172]. Both drugs are cheap and commercially available [173]. Gautret et al. [174] have also reported on the efficiency of azithromycin incorporated with hydroxychloroquine and hydroxychloroquine for the treatment of COVID-19.

Hydroxychloroquine has recently become a controversial drug due to its discouraging results. WHO has suggestedbanning hydroxychloroquine to be used for COVID-19 treatment [175] due to the adverse effects on retina tissues, cardiac muscles, central nervous system and cause genotoxicity in DNA and liver cells [176]. Initial clinical results confirmed this drug has been found anti-SARS-CoV-2 effects both in vivo and in vitro and may have an effect on the treatment of coronavirus disease [177]. These unreliable experiences have also highlighted the misleading nature of controlled experimental trials.

Favipiravir/Favilavir

Favipiravir or favilavir is an excellent antiviral [178] drug, traditionally known as Avigan and manufactured by Fujifilm [179] Toyama Chemical Company in Japan and China. Favipiravir has also been applied for coronavirus patients with improbability remains about drug effectiveness and safety [180]. However, this antiviral drug cause minor side effects [181]. The Favipiravir drug (Fig. 10) can be expressively inhibited viral clearance with a higher chest CT scan and depicted better improvement rates in moderate COVID-19 patients as compared to Lopinavir/Ritonavir [182].

Fig. 10.

Fig. 10

General structure of favipiravir

Advantages and Limitations of Natural and Synthetic Drugs

In summary, natural remedies are beneficial due to strong binding affinity, high efficacy and less side effects; whereas synthetic remedies are very reactive but indirectly may cause damage to other tissues or organs in the human body. Despite several advantages have been reported on natural and synthetic remedies, the effectiveness of both remedies is mainly depending upon the condition of patients (i.e. mild, moderate, severe, critical) and the selection of medicinal protocol. The excessive dosage of synthetic remedies, however, is very hazardous as compared to natural remedies. Natural remedies gave more advantages and safer with limited drawbacks.

Conclusion

In searching for potential remedies of antiviral drugs, the production and discovery of antiviral agents from natural and synthetic sources have been intensively developed. The outcomes of these studies indicated that drugs derived from natural resources as bioactive antiviral compounds have more potential to cure coronavirus infection as compared to synthetic drugs with less side effects. Currently, clinical tests still ongoing on the suitable and effective medical treatment of COVID-19, which authentically supports the recovery chances of patient and toxicity of the drug, the effectiveness of drug synthesis to inhibit viral infection and the replication process. This review is particularly significant in the drug discovery process and exclusively describes the potential treatments by utilizing natural and synthetic drugs against coronavirus disease. The benefit and aftereffects of both remedies have led scientists to search for more appropriate potential remedies against coronavirus ailments.

Acknowledgements

The authors would like to thank The Ministry of Higher Education Malaysia and Postgraduate Research Grant, Universiti Malaysia Sarawak for financial support.

Funding

This work was supported by The Ministry of Higher Education through F07/FRGS/1883/2019 and Universiti Malaysia Sarawak through F07/PGRS/1794/2019.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no competing interests.

Contributor Information

Saba Farooq, Email: sabafarooq61@yahoo.com.

Zainab Ngaini, Email: nzainab@unimas.my.

References

  • 1.Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Khan SA, Zia K, Ashraf S, et al. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J Biomol Struct Dyn. 2020 doi: 10.1080/07391102.2020.1751298. [DOI] [PubMed] [Google Scholar]
  • 3.Hao W, Li M, Huang X. First atypical case of 2019 novel coronavirus in Yan’an, China. Clin Microbiol Infect. 2020;26:952–953. doi: 10.1016/j.cmi.2020.02.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kang L, Li Y, Hu S, et al. The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus. Lancet Psychiatry. 2020;7:e14. doi: 10.1016/S2215-0366(20)30047-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Li M, Gu S-C, Wu X-J, et al. Extracorporeal membrane oxygenation support in 2019 novel coronavirus disease: indications, timing, and implementation. Chin Med J (Engl) 2020;133:1115–1117. doi: 10.1097/CM9.0000000000000778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020;323:709. doi: 10.1001/jama.2020.1097. [DOI] [PubMed] [Google Scholar]
  • 7.Yang T, Wang Y-C, Shen C-F, Cheng C-M. Point-of-care RNA-based diagnostic device for COVID-19. Diagnostics. 2020;10:165. doi: 10.3390/diagnostics10030165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lui RN, Wong SH, Sánchez-Luna SA, et al. Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol. 2020;35:749–759. doi: 10.1111/jgh.15053. [DOI] [PubMed] [Google Scholar]
  • 9.Lu Q, Shi Y. Coronavirus disease (COVID-19) and neonate: what neonatologist need to know. J Med Virol. 2020;92:564–567. doi: 10.1002/jmv.25740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ong SWX, Tan YK, Chia PY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020;323:1610. doi: 10.1001/jama.2020.3227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. doi: 10.1016/S0140-6736(20)30317-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400–402. doi: 10.1016/S1473-3099(20)30132-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zuo M, Huang Y, Ma W, et al. Expert recommendations for tracheal intubation in critically ill patients with noval coronavirus disease 2019. Chin Med Sci J. 2020;35:105–109. doi: 10.24920/003724. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Jiang S, Shi Z, Shu Y, et al. A distinct name is needed for the new coronavirus. Lancet. 2020;395:949. doi: 10.1016/S0140-6736(20)30419-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Bosch BJ, Martina BEE, van der Zee R, et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci. 2004;101:8455–8460. doi: 10.1073/pnas.0400576101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Huh S. How to train health personnel to protect themselves from SARS-CoV-2 (novel coronavirus) infection when caring for a patient or suspected case. J Educ Eval Health Prof. 2020;17:10. doi: 10.3352/jeehp.2020.17.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Holmes KV. SARS-associated coronavirus. N Engl J Med. 2003;348:1948–1951. doi: 10.1056/NEJMp030078. [DOI] [PubMed] [Google Scholar]
  • 19.Simmons G, Reeves JD, Rennekamp AJ, et al. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci. 2004;101:4240–4245. doi: 10.1073/pnas.0306446101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Egloff M-P, Ferron F, Campanacci V, et al. The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world. Proc Natl Acad Sci. 2004;101:3792–3796. doi: 10.1073/pnas.0307877101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Bisht H, Roberts A, Vogel L, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci. 2004;101:6641–6646. doi: 10.1073/pnas.0401939101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Lai MMC. Coronavirus: organization, replication and expression of genome. Annu Rev Microbiol. 1990;44:303–333. doi: 10.1146/annurev.mi.44.100190.001511. [DOI] [PubMed] [Google Scholar]
  • 23.Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for coronavirus disease-19 (COVID-19) Asian Pac J Allergy Immunol. 2020 doi: 10.12932/AP-200220-0773. [DOI] [PubMed] [Google Scholar]
  • 24.Jeffers SA, Tusell SM, Gillim-Ross L, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci. 2004;101:15748–15753. doi: 10.1073/pnas.0403812101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293. doi: 10.1038/s41586-020-2223-y. [DOI] [PubMed] [Google Scholar]
  • 26.Laskar P, Yallapu MM, Chauhan SC. “Tomorrow never dies”: recent advances in diagnosis, treatment, and prevention modalities against coronavirus (COVID-19) amid controversies. Diseases. 2020;8:30. doi: 10.3390/diseases8030030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Joshi S, Joshi M, Degani MS. Tackling SARS-CoV-2: proposed targets and repurposed drugs. Future Med Chem. 2020 doi: 10.4155/fmc-2020-0147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Pillaiyar T, Meenakshisundaram S, Manickam M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today. 2020;25:668–688. doi: 10.1016/j.drudis.2020.01.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Funk CD, Laferrière C, Ardakani A. A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Front Pharmacol. 2020;11:937. doi: 10.3389/fphar.2020.00937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27:325–328. doi: 10.1016/j.chom.2020.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Paraskevis D, Kostaki EG, Magiorkinis G, et al. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol. 2020;79:104212. doi: 10.1016/j.meegid.2020.104212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect. 2020 doi: 10.1016/j.jmii.2020.03.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Chou K-C, Wei D-Q, Zhong W-Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun. 2003;308:148–151. doi: 10.1016/S0006-291X(03)01342-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Ho W. Guideline on management of severe acute respiratory syndrome (SARS) Lancet. 2003;361:1313–1315. doi: 10.1016/S0140-6736(03)13085-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Xu X. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res. 2003;31:7117–7130. doi: 10.1093/nar/gkg916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Fouchier RAM, Hartwig NG, Bestebroer TM, et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci. 2004;101:6212–6216. doi: 10.1073/pnas.0400762101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Yang N, Tanner JA, Wang Z, et al. Inhibition of SARS coronavirus helicase by bismuth complexes. Chem Commun. 2007 doi: 10.1039/b709515e. [DOI] [PubMed] [Google Scholar]
  • 38.Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004;10:290–293. doi: 10.1038/nm1001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.de Wit E, Rasmussen AL, Falzarano D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci. 2013;110:16598–16603. doi: 10.1073/pnas.1310744110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Yang Y, Du L, Liu C, et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci. 2014;111:12516–12521. doi: 10.1073/pnas.1405889111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Wang F, Chen C, Tan W, et al. Structure of main protease from human coronavirus NL63: insights for wide spectrum anti-coronavirus drug design. Sci Rep. 2016;6:22677. doi: 10.1038/srep22677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ramshaw RE, Letourneau ID, Hong AY, et al. A database of geopositioned Middle East Respiratory Syndrome Coronavirus occurrences. Sci Data. 2019;6:318. doi: 10.1038/s41597-019-0330-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Kim Y, Liu H, Galasiti Kankanamalage AC, et al. Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLOS Pathog. 2016;12:e1005531. doi: 10.1371/journal.ppat.1005531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Prator C, Thanh C, Kumar S, et al. Circulating CD30+ CD4+ T Cells increase prior to HIV rebound following analytical antiretroviral treatment interruption. J Infect Dis. 2019;221:1146–1155. doi: 10.1093/infdis/jiz572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Li C-C, Wang X-J, Wang H-CR. Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discov Today. 2019;24:726–736. doi: 10.1016/j.drudis.2019.01.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020;40:68–76. doi: 10.1080/01652176.2020.1727993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Wang L-F, Shi Z, Zhang S, et al. Review of bats and SARS. Emerg Infect Dis. 2006;12:1834–1840. doi: 10.3201/eid1212.060401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Ren L-L, Wang Y-M, Wu Z-Q, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl) 2020;133:1015–1024. doi: 10.1097/CM9.0000000000000722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Zhang J, Ma K, Li H, et al. The continuous evolution and dissemination of 2019 novel human coronavirus. J Infect. 2020;80:671–693. doi: 10.1016/j.jinf.2020.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.McIntosh K, et al. Coronaviruses: a comparative review. In: Arber W, Haas R, Henle W, et al., editors. Current topics in microbiology and immunology/Ergebnisse der Mikrobiologie und Immunitätsforschung. Berlin: Springer; 1974. pp. 85–129. [Google Scholar]
  • 51.Herrewegh AAPM, Smeenk I, Horzinek MC, et al. Feline coronavirus type II strains 79–1683 and 79–1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. J Virol. 1998;72:4508–4514. doi: 10.1128/JVI.72.5.4508-4514.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Tang JW, Tambyah PA, Hui DSC. Emergence of a novel coronavirus causing respiratory illness from Wuhan, China. J Infect. 2020;80:350–371. doi: 10.1016/j.jinf.2020.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94:e00127–e220. doi: 10.1128/JVI.00127-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Peiris JSM, Lai ST, Poon LLM, et al. Coronavirus as a possible cause of severe acute respiratory. Lancet. 2003;361:7. doi: 10.1016/S0140-6736(03)13077-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Berry M, Fielding B, Gamieldien J. Potential broad spectrum inhibitors of the coronavirus 3CLpro: a virtual screening and structure-based drug design study. Viruses. 2015;7:6642–6660. doi: 10.3390/v7122963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.McDermott MM, Newman AB. Preserving clinical trial integrity during the coronavirus pandemic. JAMA. 2020;323:2135. doi: 10.1001/jama.2020.4689. [DOI] [PubMed] [Google Scholar]
  • 57.Weng L, Shi Y, Xiao T, et al. Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (first edition) Ann Transl Med. 2020;8:47–47. doi: 10.21037/atm.2020.02.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Sharfstein JM, Becker SJ, Mello MM. Diagnostic testing for the novel coronavirus. JAMA. 2020;323:1437. doi: 10.1001/jama.2020.3864. [DOI] [PubMed] [Google Scholar]
  • 59.Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239. doi: 10.1001/jama.2020.2648. [DOI] [PubMed] [Google Scholar]
  • 60.Zhou P, Huang Z, Xiao Y, et al. Protecting Chinese healthcare workers while combating the 2019 novel coronavirus. Infect Control Hosp Epidemiol. 2020;41:745–746. doi: 10.1017/ice.2020.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Khan S, Siddique R, Ali A, et al. Novel coronavirus, poor quarantine, and the risk of pandemic. J Hosp Infect. 2020;104:449–450. doi: 10.1016/j.jhin.2020.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Gostin L, Hodge J. US emergency legal responses to novel coronavirus: balancing public health and civil liberties. JAMA. 2020;323:1131–1132. doi: 10.1001/jama.2020.2025. [DOI] [PubMed] [Google Scholar]
  • 63.Liu S-L, Saif L. Emerging viruses without borders: the Wuhan coronavirus. Viruses. 2020;12:130. doi: 10.3390/v12020130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Santosh KC. AI-driven tools for coronavirus outbreak: need of active learning and cross-population train/test models on multitudinal/multimodal data. J Med Syst. 2020;44:93. doi: 10.1007/s10916-020-01562-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450–452. doi: 10.1038/s41591-020-0820-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Chang D, Xu H, Rebaza A, et al. Protecting health-care workers from subclinical coronavirus infection. Lancet Respir Med. 2020;8:e13. doi: 10.1016/S2213-2600(20)30066-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–473. doi: 10.1016/S0140-6736(20)30185-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Cheng VCC, Wong S-C, To KKW, et al. Preparedness and proactive infection control measures against the emerging novel coronavirus in China. J Hosp Infect. 2020;104:254–255. doi: 10.1016/j.jhin.2020.01.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Khurshid Z, Asiri FYI, Al Wadaani H. Human saliva: non-invasive fluid for detecting novel coronavirus (2019-nCoV) Int J Environ Res Public Health. 2020;17:2225. doi: 10.3390/ijerph17072225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Yi Y, Lagniton PNP, Ye S, et al. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16:1753–1766. doi: 10.7150/ijbs.45134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 2020;5:751. doi: 10.1001/jamacardio.2020.1105. [DOI] [PubMed] [Google Scholar]
  • 72.Lakkireddy DR, Chung MK, Gopinathannair R, et al. Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 task force; electrophysiology section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. Heart Rhythm. 2020 doi: 10.1016/j.hrthm.2020.03.028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Chiappelli F. Putative natural history of CoViD-19. Bioinformation. 2020;16:398–403. doi: 10.6026/97320630016398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Chang D, Lin M, Wei L, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA. 2020;323:1092. doi: 10.1001/jama.2020.1623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Naicker S, Yang C-W, Hwang S-J, et al. The novel coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97:824–828. doi: 10.1016/j.kint.2020.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Tang B, Li S, Xiong Y, et al. COVID-19 pneumonia in a hemodialysis patient. Kidney Med. 2020;2:354–358. doi: 10.1016/j.xkme.2020.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2:100113. doi: 10.1016/j.jhepr.2020.100113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Xiang Y-T, Yang Y, Li W, et al. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. Lancet Psychiatry. 2020;7:228–229. doi: 10.1016/S2215-0366(20)30046-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Liu D, Li L, Wu X, et al. Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: a preliminary analysis. Am J Roentgenol. 2020;215:127–132. doi: 10.2214/AJR.20.23072. [DOI] [PubMed] [Google Scholar]
  • 80.Sun F, Ganguli A, Nguyen J, et al. Smartphone-based multiplex 30-minute nucleic acid test of live virus from nasal swab extract. Lab Chip. 2020;20:1621–1627. doi: 10.1039/D0LC00304B. [DOI] [PubMed] [Google Scholar]
  • 81.Yan C, Cui J, Huang L, et al. Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay. Clin Microbiol Infect. 2020;26:773–779. doi: 10.1016/j.cmi.2020.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Nguyen T, Duong Bang D, Wolff A. 2019 Novel coronavirus disease (COVID-19): paving the road for rapid detection and point-of-care diagnostics. Micromachines. 2020;11:306. doi: 10.3390/mi11030306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Khan AU, Proma AA, Akter M, et al. A review on coronavirus disease (COVID-19) epidemic threat for global health in 2020. Am J Microbiol Res. 2020;8:57–62. doi: 10.12691/ajmr-8-2-3. [DOI] [Google Scholar]
  • 84.Tan ELC, Ooi EE, Lin C-Y, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis. 2004;10:581–586. doi: 10.3201/eid1004.030458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci. 2004;101:2536–2541. doi: 10.1073/pnas.0307140101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Cinatljr J, Michaelis M, Hoever G, et al. Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Res. 2005;66:81–97. doi: 10.1016/j.antiviral.2005.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Durai P, Batool M, Shah M, Choi S. Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control. Exp Mol Med. 2015;47:e181–e181. doi: 10.1038/emm.2015.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Baseler L, de Wit E, Feldmann H. A comparative review of animal models of middle east respiratory syndrome coronavirus infection. Vet Pathol. 2016;53:521–531. doi: 10.1177/0300985815620845. [DOI] [PubMed] [Google Scholar]
  • 89.Momattin H, Al-Ali AY, Al-Tawfiq JA. A systematic review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Travel Med Infect Dis. 2019;30:9–18. doi: 10.1016/j.tmaid.2019.06.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Weber DJ, Sickbert-Bennett EE, Kanamori H, Rutala WA. New and emerging infectious diseases (Ebola, Middle Eastern respiratory syndrome coronavirus, carbapenem-resistant Enterobacteriaceae, Candida auris): focus on environmental survival and germicide susceptibility. Am J Infect Control. 2019;47:A29–A38. doi: 10.1016/j.ajic.2019.03.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil Med Res. 2020;7:11. doi: 10.1186/s40779-020-00240-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020 doi: 10.1001/jama.2020.6019. [DOI] [PubMed] [Google Scholar]
  • 93.Xiao S, Wu Y, Liu H. Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring. J Med Virol. 2020;92:464–467. doi: 10.1002/jmv.25702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. J Med Virol. 2020;92:479–490. doi: 10.1002/jmv.25707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion (Paris) 2005;45:580–590. doi: 10.1111/j.0041-1132.2005.04316.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Eickmann M, Gravemann U, Handke W, et al. Inactivation of three emerging viruses—severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus—in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light. Vox Sang. 2020;115:146–151. doi: 10.1111/vox.12888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Yunoki M, Urayama T, Yamamoto I, et al. Heat sensitivity of a SARS-associated coronavirus introduced into plasma products. Vox Sang. 2004;87:302–303. doi: 10.1111/j.1423-0410.2004.00577.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Darnell MER, Taylor DR. Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products. Transfusion (Paris) 2006;46:1770–1777. doi: 10.1111/j.1537-2995.2006.00976.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Martinez JP, Sasse F, Brönstrup M, et al. Antiviral drug discovery: broad-spectrum drugs from nature. Nat Prod Rep. 2015;32:29–48. doi: 10.1039/C4NP00085D. [DOI] [PubMed] [Google Scholar]
  • 100.Dhama K, Karthik K, Khandia R, et al. Medicinal and therapeutic potential of herbs and plant metabolites/extracts countering viral pathogens—current knowledge and future prospects. Curr Drug Metab. 2018;19:236–263. doi: 10.2174/1389200219666180129145252. [DOI] [PubMed] [Google Scholar]
  • 101.Grienke U, Schmidtke M, von Grafenstein S, et al. Influenza neuraminidase: a druggable target for natural products. Nat Prod Rep. 2012;29:11–36. doi: 10.1039/C1NP00053E. [DOI] [PubMed] [Google Scholar]
  • 102.Lin L-T, Hsu W-C, Lin C-C. Antiviral natural products and herbal medicines. J Tradit Complement Med. 2014;4:24–35. doi: 10.4103/2225-4110.124335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Salim B, Noureddine M (2020) Identification of compounds from nigella sativa as new potential inhibitors of 2019 novel coronasvirus (Covid-19): molecular docking study. Preprint: ChemRxiv.
  • 104.Bhagya N, Chandrashekar KR. Tetrandrine—a molecule of wide bioactivity. Phytochemistry. 2016;125:5–13. doi: 10.1016/j.phytochem.2016.02.005. [DOI] [PubMed] [Google Scholar]
  • 105.Yang Y, Islam MS, Wang J, et al. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci. 2020;16:1708–1717. doi: 10.7150/ijbs.45538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Kim DE, Min JS, Jang MS, et al. Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells. Biomolecules. 2019;9:696. doi: 10.3390/biom9110696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Mohammadi N, Shaghaghi N (2020) inhibitory effect of eight secondary metabolites from conventional medicinal plants on COVID_19 virus protease by molecular docking analysis. Preprint. 10.26434/chemrxiv.11987475.v1
  • 108.Luo E, Zhang D, Luo H, et al. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China. Chin Med. 2020;15:34. doi: 10.1186/s13020-020-00317-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Luo H, Tang Q, Shang Y, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? a review of historical classics, research evidence and current prevention programs. Chin J Integr Med. 2020;26:243–250. doi: 10.1007/s11655-020-3192-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020;24:91. doi: 10.1186/s13054-020-2818-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Li Y, Liu X, Guo L, et al. Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis. Syst Rev. 2020;9:75. doi: 10.1186/s13643-020-01343-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11:2251. doi: 10.1038/s41467-020-16256-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Casadevall A, Pirofski L. The convalescent sera option for containing COVID-19. J Clin Investig. 2020;130:1545–1548. doi: 10.1172/JCI138003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8. doi: 10.1016/j.cell.2020.02.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Tiberghien P, Lamballerie X, Morel P, et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. 2020 doi: 10.1111/vox.12926. [DOI] [PubMed] [Google Scholar]
  • 116.Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20:398–400. doi: 10.1016/S1473-3099(20)30141-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117.Keith P, Day M, Perkins L, et al. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 2020;24:128. doi: 10.1186/s13054-020-2836-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Roback J, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020;323:1561. doi: 10.1001/jama.2020.4940. [DOI] [PubMed] [Google Scholar]
  • 119.Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.He F, Deng Y, Li W. Coronavirus disease 2019: what we know? J Med Virol. 2020;92:719–725. doi: 10.1002/jmv.25766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Lei C, Qian K, Li T, et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun. 2020;11:2070. doi: 10.1038/s41467-020-16048-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55:105948. doi: 10.1016/j.ijantimicag.2020.105948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest. 2020;158:e9–e13. doi: 10.1016/j.chest.2020.03.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Rahman N, Basharat Z, Yousuf M, et al. Virtual screening of natural products against type II transmembrane serine protease (TMPRSS2), the priming agent of coronavirus 2 (SARS-CoV-2) Molecules. 2020;25:2271. doi: 10.3390/molecules25102271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Suwannarach N, Kumla J, Sujarit K, et al. Natural bioactive compounds from fungi as potential candidates for protease inhibitors and immunomodulators to apply for coronaviruses. Molecules. 2020;25:1800. doi: 10.3390/molecules25081800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Patel RS, Vanzara AG, Patel NR, et al (2020) Discovery of fungal metabolites bergenin, quercitrin and dihydroartemisinin as potential inhibitors against main protease of SARS-CoV-2. Preprint: ChemRxiv.
  • 127.Sang VT, Hung ND, Se-kwon K. Pharmaceutical properties of marine polyphenols: an overview. ACTA Pharm Sci. 2019;57:217. doi: 10.23893/1307-2080.APS.05714. [DOI] [Google Scholar]
  • 128.Chojnacka K, Witek-Krowiak A, Skrzypczak D, et al. Phytochemicals containing biologically active polyphenols as an effective agent against Covid-19-inducing coronavirus. J Funct Foods. 2020;73:104146. doi: 10.1016/j.jff.2020.104146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Gentile D, Patamia V, Scala A, et al. Putative inhibitors of SARS-CoV-2 main protease from a library of marine natural products: a virtual screening and molecular modeling study. Mar Drugs. 2020;18:225. doi: 10.3390/md18040225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Masterson CH, Murphy EJ, Gonzalez H, et al. Purified β-glucans from the Shiitake mushroom ameliorates antibiotic-resistant Klebsiella pneumoniae-induced pulmonary sepsis. Lett Appl Microbiol. 2020 doi: 10.1111/lam.13358. [DOI] [PubMed] [Google Scholar]
  • 131.Frankenberg R. Allopathic medicine, profession, and capitalist ideology in India. Soc Sci Med Part Med Psychol Med Sociol. 1981;15:115–125. doi: 10.1016/0271-7123(81)90031-6. [DOI] [PubMed] [Google Scholar]
  • 132.Liu K, Fang Y-Y, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020;133:1025–1031. doi: 10.1097/CM9.0000000000000744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Zhang J, Zhou L, Yang Y, et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med. 2020;8:e11–e12. doi: 10.1016/S2213-2600(20)30071-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Ghosh AK, Chapsal BD (2013) Design of the anti-HIV protease inhibitor darunavir. In: Introduction to biological and small molecule drug research and development. Elsevier, pp 355–384. 10.1016/B978-0-12-397176-0.00013-3
  • 135.Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev. 2020;34:75–80. doi: 10.1016/j.tmrv.2020.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136.Muralidharan N, Sakthivel R, Velmurugan D, Gromiha MM. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J Biomol Struct Dyn. 2020 doi: 10.1080/07391102.2020.1752802. [DOI] [PubMed] [Google Scholar]
  • 137.Karimi A, Rafiei Tabatabaei S, Rajabnejad M, et al. An algorithmic approach to diagnosis and treatment of coronavirus disease 2019 (COVID-19) in children: Iranian expert’s consensus statement. Arch Pediatr Infect Dis. 2020 doi: 10.5812/pedinfect.102400. [DOI] [Google Scholar]
  • 138.Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19) Drug Discov Ther. 2020;14:58–60. doi: 10.5582/ddt.2020.01012. [DOI] [PubMed] [Google Scholar]
  • 139.Mohammed Hamad MN. Minocycline superior to chloroquine phosphate as COVID-19 treatment. Saudi J Biomed Res. 2020;05:46–47. doi: 10.36348/sjbr.2020.v05i03.006. [DOI] [Google Scholar]
  • 140.Esposito S, Noviello S, Pagliano P. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Le Infezioni Med. 2020;2:198–211. [PubMed] [Google Scholar]
  • 141.Sahin AR. 2019 novel coronavirus (COVID-19) outbreak: a review of the current literature. Eurasian J Med Oncol. 2020 doi: 10.14744/ejmo.2020.12220. [DOI] [Google Scholar]
  • 142.Yamini RS. Drug repositioning in the treatment Of Covid-19. J Med Pharm Allied Sci. 2020;9:2412–2417. doi: 10.22270/jmpas.v9i1.903. [DOI] [Google Scholar]
  • 143.Avchaciov K, Burmistrova O, Fedichev P. AI for the repurposing of approved or investigational drugs against COVID-19. Research Gate. 2020 doi: 10.13140/RG.2.2.20588.10886. [DOI] [Google Scholar]
  • 144.Alam MN (2020) Recent progress in the treatment of coronavirus disease. OSF Preprints. 10.31219/osf.io/6bvu4
  • 145.Matsuyama S, Kawase M, Nao N et al (2020) The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. Preprint, BioRxiv. 10.1101/2020.03.11.987016
  • 146.Dzieciatkowski T, Szarpak L, Filipiak KJ, et al. COVID-19 challenge for modern medicine. Cardiol J. 2020;27:9. doi: 10.5603/CJ.a2020.0055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 147.Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367:1412–1413. doi: 10.1126/science.367.6485.1412. [DOI] [PubMed] [Google Scholar]
  • 148.Rios P, Radhakrishnan A, Antony J et al (2020) Effectiveness and safety of antiviral or antibody treatments for coronavirus. Preprint, medRxiv. 10.1101/2020.03.19.20039008
  • 149.Gonzalez Paz LA, Lossada CA, Moncayo LS et al (2020) Molecular docking and molecular dynamic study of two viral proteins associated with SARS-CoV-2 with ivermectin. Preprints, 2020040334. 10.20944/preprints202004.0334.v1
  • 150.Dasgupta J, Sen U, Bakshi A et al (2020) Nsp7 and spike glycoprotein of SARS-CoV-2 are envisaged as potential targets of vitamin D and ivermectin. Preprints, 2020050084. 10.20944/preprints202005.0084.v1
  • 151.Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443:851–856. doi: 10.1042/BJ20120150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152.Kosyna FK, Nagel M, Kluxen L, et al. The importin α/β-specific inhibitor ivermectin affects HIF-dependent hypoxia response pathways. Biol Chem. 2015;396:1357–1367. doi: 10.1515/hsz-2015-0171. [DOI] [PubMed] [Google Scholar]
  • 153.Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi: 10.1016/j.antiviral.2020.104787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 154.Kong R, Yang G, Xue R, et al (2020) COVID-19 docking server: an interactive server for docking small molecules, peptides and antibodies against potential targets of COVID-19. arXiv preprint arXiv:2003.00163. 10.1093/bioinformatics/btaa645 [DOI] [PMC free article] [PubMed]
  • 155.del Rio C, Malani PN. 2019 novel coronavirus—important information for clinicians. JAMA. 2020;323:1039. doi: 10.1001/jama.2020.1490. [DOI] [PubMed] [Google Scholar]
  • 156.Gordon CJ, Tchesnokov EP, Feng JY, et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295:4773–4779. doi: 10.1074/jbc.AC120.013056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157.Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929–936. doi: 10.1056/NEJMoa2001191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 158.Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578. doi: 10.1016/S0140-6736(20)31022-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159.Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 160.Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) Biosci Trends. 2020;14:69–71. doi: 10.5582/bst.2020.01020. [DOI] [PubMed] [Google Scholar]
  • 161.Keyaerts E, Vijgen L, Maes P, et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323:264–268. doi: 10.1016/j.bbrc.2004.08.085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 162.Salvi R, Patankar P. Emerging pharmacotherapies for COVID-19. Biomed Pharmacother. 2020;128:110267. doi: 10.1016/j.biopha.2020.110267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 163.Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020;55:105945. doi: 10.1016/j.ijantimicag.2020.105945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 164.Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;177:104762. doi: 10.1016/j.antiviral.2020.104762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 165.Lucchesi A, Silimbani P, Musuraca G, et al. Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease. J Med Virol. 2020 doi: 10.1002/jmv.26217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 166.Devi S, Kumar M, Upadhyay PK, et al. An overview of novel corona virus 2019-nCoV and their clinical and immune responses. Int J Res Pharm Sci. 2020;11:62–67. doi: 10.26452/ijrps.v11iSPL1.2188. [DOI] [Google Scholar]
  • 167.Chong VH, Chong PL, Metussin D, et al. Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19. J Med Virol. 2020 doi: 10.1002/jmv.26004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168.Khuroo MS. Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. Int J Antimicrob Agents. 2020 doi: 10.1016/j.ijantimicag.2020.106101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 169.Shittu MO, Afolami OI. Improving the efficacy of chloroquine and hydroxychloroquine against SARS-CoV-2 may require zinc additives—a better synergy for future COVID-19 clinical trials. Infez Med. 2020;28:192–197. [PubMed] [Google Scholar]
  • 170.Garcia-Cremades M, Solans BP, Hughes E, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther. 2020;108:253–263. doi: 10.1002/cpt.1856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 171.Deniz O (2020) Hydroxychloroquine; why it might be successful and why it might not be successful in the treatment of Covid-19 pneumonia? Could it be a prophylactic drug? Preprints, 2020040348. 10.20944/preprints202004.0348.v3
  • 172.Andreani J, Le Bideau M, Duflot I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020;145:104228. doi: 10.1016/j.micpath.2020.104228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 173.Gautret P, Lagier J-C, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;34:101663. doi: 10.1016/j.tmaid.2020.101663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 174.Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949. doi: 10.1016/j.ijantimicag.2020.105949. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 175.Diotallevi F, Campanati A, Radi G, et al. Hydroxychloroquine, dermatology, and SARS-CoV-2: updating an old association. J Med Virol. 2020 doi: 10.1002/jmv.26322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 176.Pereira BB. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review. J Toxicol Environ Health Part B. 2020;23:177–181. doi: 10.1080/10937404.2020.1752340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 177.Zou L, Dai L, Zhang X, et al. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. Arch Pharm Res. 2020 doi: 10.1007/s12272-020-01258-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 178.Abou Zeid L (2020) Computational lead discovery for COVID-19 recovery. Favilavir isostere analog as promising remedy of corona viral infection, Laila A Abou-Zeid; Associate Professor. FOP, Delta University & Mansoura University
  • 179.Rich RL, Myszka DG. Kinetic analysis and fragment screening with Fujifilm AP-3000. Anal Biochem. 2010;402:170–178. doi: 10.1016/j.ab.2010.03.043. [DOI] [PubMed] [Google Scholar]
  • 180.Arab-Zozani M, Hassanipour S, GHoddoosi-Nejad DJ. Favipiravir for treating novel coronavirus (COVID-19) patients: protocol for a systematic review and meta-analysis of controlled trials. medRxiv. 2020 doi: 10.1101/2020.04.27.20081471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 181.Jahangir M. Coronavirus (COVID-19): history, current knowledge and pipeline medications. Int J Pharm Pharmacol. 2020;4:1–9. doi: 10.31531/2581-3080.1000140. [DOI] [Google Scholar]
  • 182.Lan X, Shao C, Zeng X, et al. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study. medRxiv. 2020 doi: 10.1101/2020.04.25.20079079. [DOI] [PubMed] [Google Scholar]

Articles from Chemistry Africa are provided here courtesy of Nature Publishing Group

RESOURCES